Press

Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803

Sep 27 • 3 min read

Tryp Therapeutics, Inc. (CSE: TRYP | OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. One patent application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other application, #63/375,305,…

Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future

Sep 26 • 3 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. has opened their new Clinical Research Center in London, Ontario, with…

Universal Ibogaine Featured in Psychedelics Tonight Documentary Series

Sep 26 • 2 min read

Universal Ibogaine Inc.(TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to announce it has been featured in a documentary series entitled Psychedelics Tonight, which was co-produced by Kyle Buller and Joe Moore of Psychedelics Today in partnership with ALTRD.TV. The docuseries provides information on the history and future potential of several…

Clearmind Announces Notice of Proposed Stock Consolidation

Sep 25 • 2 min read

Clearmind Medicine Inc. (CSE: CMND | OTC Pink: CMNDF | FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announces that it will be consolidating all of the issued and outstanding common shares of the Company on the basis of one (1) post consolidation…

Irwin Naturals Inc Announces Normal Course Issuer Bid for Subordinate Voting Shares of the Corporation

Sep 24 • 3 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) announced today its intention to commence a normal course issuer bid, under which the Company may purchase up to 75,466 of the Company’s Subordinate Voting Shares over a 12-month period, representing approximately 5% of its issued and outstanding SVS as of September 26, 2022. The Company is…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441